QQQ   437.19 (+0.15%)
AAPL   180.86 (-0.17%)
MSFT   405.66 (-0.46%)
META   483.79 (+0.43%)
GOOGL   137.91 (+0.25%)
AMZN   174.29 (-0.25%)
TSLA   202.11 (+1.36%)
NVDA   791.92 (+0.13%)
NIO   5.79 (+2.48%)
AMD   178.18 (+1.23%)
BABA   77.44 (+1.22%)
T   16.65 (+0.30%)
F   12.10 (+1.26%)
MU   91.24 (+1.99%)
CGC   3.56 (+2.59%)
GE   153.84 (-0.60%)
DIS   108.46 (+0.72%)
AMC   4.68 (+5.17%)
PFE   27.00 (-0.66%)
PYPL   59.74 (+0.69%)
XOM   104.36 (+0.11%)
QQQ   437.19 (+0.15%)
AAPL   180.86 (-0.17%)
MSFT   405.66 (-0.46%)
META   483.79 (+0.43%)
GOOGL   137.91 (+0.25%)
AMZN   174.29 (-0.25%)
TSLA   202.11 (+1.36%)
NVDA   791.92 (+0.13%)
NIO   5.79 (+2.48%)
AMD   178.18 (+1.23%)
BABA   77.44 (+1.22%)
T   16.65 (+0.30%)
F   12.10 (+1.26%)
MU   91.24 (+1.99%)
CGC   3.56 (+2.59%)
GE   153.84 (-0.60%)
DIS   108.46 (+0.72%)
AMC   4.68 (+5.17%)
PFE   27.00 (-0.66%)
PYPL   59.74 (+0.69%)
XOM   104.36 (+0.11%)
QQQ   437.19 (+0.15%)
AAPL   180.86 (-0.17%)
MSFT   405.66 (-0.46%)
META   483.79 (+0.43%)
GOOGL   137.91 (+0.25%)
AMZN   174.29 (-0.25%)
TSLA   202.11 (+1.36%)
NVDA   791.92 (+0.13%)
NIO   5.79 (+2.48%)
AMD   178.18 (+1.23%)
BABA   77.44 (+1.22%)
T   16.65 (+0.30%)
F   12.10 (+1.26%)
MU   91.24 (+1.99%)
CGC   3.56 (+2.59%)
GE   153.84 (-0.60%)
DIS   108.46 (+0.72%)
AMC   4.68 (+5.17%)
PFE   27.00 (-0.66%)
PYPL   59.74 (+0.69%)
XOM   104.36 (+0.11%)
QQQ   437.19 (+0.15%)
AAPL   180.86 (-0.17%)
MSFT   405.66 (-0.46%)
META   483.79 (+0.43%)
GOOGL   137.91 (+0.25%)
AMZN   174.29 (-0.25%)
TSLA   202.11 (+1.36%)
NVDA   791.92 (+0.13%)
NIO   5.79 (+2.48%)
AMD   178.18 (+1.23%)
BABA   77.44 (+1.22%)
T   16.65 (+0.30%)
F   12.10 (+1.26%)
MU   91.24 (+1.99%)
CGC   3.56 (+2.59%)
GE   153.84 (-0.60%)
DIS   108.46 (+0.72%)
AMC   4.68 (+5.17%)
PFE   27.00 (-0.66%)
PYPL   59.74 (+0.69%)
XOM   104.36 (+0.11%)

Vanda Pharmaceuticals (VNDA) Stock Price, News & Analysis

$4.67
+0.11 (+2.41%)
(As of 12:04 PM ET)
Today's Range
$4.62
$4.76
50-Day Range
$3.47
$4.56
52-Week Range
$3.30
$7.00
Volume
484,762 shs
Average Volume
1.01 million shs
Market Capitalization
$268.71 million
P/E Ratio
93.42
Dividend Yield
N/A
Price Target
N/A

Vanda Pharmaceuticals MarketRank™ Stock Analysis

Analyst Rating
N/A
Upside/​Downside
N/A
Short Interest
Healthy
3.98% of Shares Sold Short
Dividend Strength
N/A
Sustainability
-1.77
Upright™ Environmental Score
News Sentiment
N/A
Insider Trading
N/A
Proj. Earnings Growth
Decreasing
From $0.01 to ($0.48) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

3.05 out of 5 stars

Medical Sector

410th out of 942 stocks

Pharmaceutical Preparations Industry

179th out of 427 stocks


VNDA stock logo

About Vanda Pharmaceuticals Stock (NASDAQ:VNDA)

Vanda Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of therapies to address high unmet medical needs worldwide. The company's marketed products include HETLIOZ to treat non-24-hour sleep-wake disorders; and Fanapt oral tablets for the treatment of schizophrenia. Its pipeline products include HETLIOZ (tasimelteon) to treat jet lag disorder, insomnia, delayed sleep phase disorder, sleep disturbances in autism spectrum disorder, and pediatric Non-24; Fanapt (iloperidone) for the treatment of bipolar I disorder and Parkinson's disease psychosis, as well as a long acting injectable (LAI) formulation to treat schizophrenia; and Tradipitant (VLY-686), a small molecule neurokinin-1 receptor (NK-1R) antagonist to treat gastroparesis, motion sickness, atopic dermatitis, and COVID-19 pneumonia. The company's pipeline products also include VTR-297, a small molecule histone deacetylase inhibitor to treat hematologic malignancies and with potential use as a treatment for various oncology indications; VQW-765, a small molecule nicotinic acetylcholine receptor partial agonist to treat performance anxiety and psychiatric disorders; VHX-896, an active metabolite of iloperidone; and antisense oligonucleotide molecules. In addition, it offers a portfolio of cystic fibrosis transmembrane conductance regulator activators and inhibitors that include VSJ-110 for the treatment of dry eye and ocular inflammation; and VPO-227 for the treatment of secretory diarrhea disorders comprising cholera. Vanda Pharmaceuticals Inc. was incorporated in 2002 and is headquartered in Washington, the District of Columbia.

VNDA Stock Price History

VNDA Stock News Headlines

VNDA Sep 2024 3.000 put
VNDA Sep 2024 3.000 call
Energy Storage Trend Ignites Frenzy Over Vanadium Supply
As the world shifts to renewables such as wind and solar, how will we store all this energy? Vanadium batteries are the breakthrough that some experts predict will be the future of grid-scale energy storage. The problem is, only 5% of vanadium is mined in the U.S. - and China and Russia have a stranglehold on our supply.
Energy Storage Trend Ignites Frenzy Over Vanadium Supply
As the world shifts to renewables such as wind and solar, how will we store all this energy? Vanadium batteries are the breakthrough that some experts predict will be the future of grid-scale energy storage. The problem is, only 5% of vanadium is mined in the U.S. - and China and Russia have a stranglehold on our supply.
Q4 2023 Vanda Pharmaceuticals Inc Earnings Call
Vanda Pharma Announces U.S. Patent Allowance For PONVORY
See More Headlines
Receive VNDA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Vanda Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
11/03/2021
Today
2/27/2024
Next Earnings (Estimated)
5/01/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
Biotechnology
Current Symbol
NASDAQ:VNDA
CUSIP
92165910
Employees
203
Year Founded
2002

Profitability

Net Income
$2.51 million
Pretax Margin
3.29%

Debt

Sales & Book Value

Annual Sales
$192.64 million
Book Value
$9.47 per share

Miscellaneous

Free Float
53,107,000
Market Cap
$262.38 million
Optionable
Optionable
Beta
0.68

Social Links

12 Stocks Corporate Insiders are Abandoning Cover

If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know?

Get This Free Report














VNDA Stock Analysis - Frequently Asked Questions

How have VNDA shares performed in 2024?

Vanda Pharmaceuticals' stock was trading at $4.22 at the start of the year. Since then, VNDA shares have increased by 10.4% and is now trading at $4.66.
View the best growth stocks for 2024 here
.

Are investors shorting Vanda Pharmaceuticals?

Vanda Pharmaceuticals saw a increase in short interest in January. As of January 31st, there was short interest totaling 2,290,000 shares, an increase of 30.9% from the January 15th total of 1,750,000 shares. Based on an average trading volume of 1,000,000 shares, the days-to-cover ratio is currently 2.3 days.
View Vanda Pharmaceuticals' Short Interest
.

When is Vanda Pharmaceuticals' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, May 1st 2024.
View our VNDA earnings forecast
.

How were Vanda Pharmaceuticals' earnings last quarter?

Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) announced its quarterly earnings data on Wednesday, November, 3rd. The biopharmaceutical company reported $0.14 EPS for the quarter, missing analysts' consensus estimates of $0.20 by $0.06. The biopharmaceutical company earned $70.10 million during the quarter, compared to analyst estimates of $73.50 million. Vanda Pharmaceuticals had a net margin of 1.30% and a trailing twelve-month return on equity of 0.46%. During the same quarter in the previous year, the firm earned $0.11 EPS.

What ETFs hold Vanda Pharmaceuticals' stock?

ETFs with the largest weight of Vanda Pharmaceuticals (NASDAQ:VNDA) stock in their portfolio include Virtus LifeSci Biotech Products ETF (BBP), Horizon Kinetics Medical ETF (MEDX), iShares Neuroscience and Healthcare ETF (IBRN), iShares U.S. Pharmaceuticals ETF (IHE),

What is Mihael H. Polymeropoulos' approval rating as Vanda Pharmaceuticals' CEO?

12 employees have rated Vanda Pharmaceuticals Chief Executive Officer Mihael H. Polymeropoulos on Glassdoor.com. Mihael H. Polymeropoulos has an approval rating of 24% among the company's employees. This puts Mihael H. Polymeropoulos in the bottom 10% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Vanda Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Vanda Pharmaceuticals investors own include FibroGen (FGEN), Zogenix (ZGNX), Inovio Pharmaceuticals (INO), NVIDIA (NVDA), Gilead Sciences (GILD), Exelixis (EXEL), Sangamo Therapeutics (SGMO), Array Technologies (ARRY), Micron Technology (MU) and Novavax (NVAX).

Who are Vanda Pharmaceuticals' major shareholders?

Vanda Pharmaceuticals' stock is owned by a variety of institutional and retail investors. Top institutional shareholders include Vanguard Group Inc. (6.01%), Dimensional Fund Advisors LP (3.42%), Nantahala Capital Management LLC (1.76%), Federated Hermes Inc. (1.42%), GSA Capital Partners LLP (0.99%) and Northern Trust Corp (0.88%). Insiders that own company stock include Aranthan Jones II, Gunther Birznieks, Joakim Wijkstrom, Kevin Patrick Moran, Melissa Young, Mihael Hristos Polymeropoulos, Phaedra Chrousos, Richard W Dugan, Stephen Ray Mitchell and Timothy Williams.
View institutional ownership trends
.

How do I buy shares of Vanda Pharmaceuticals?

Shares of VNDA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:VNDA) was last updated on 2/27/2024 by MarketBeat.com Staff